An efficient extraction of doxorubicin (Dox) from homemade stealth hyalurionic acid (HA)-based nanoparticles (NPs) in rat plasma could not be performed by previously published methods. Therefore, we attempted to establish the novel NPs-breaking and UPLC-MS-MS method for evaluating the pharmacokinetic profiles of the homemade stealth HA NPs in rats. The pretreatment method of plasma samples used the liquid-liquid extraction method with isopropyl alcohol as NPs-breaking and protein-precipitating solvents, and the NPs-breaking efficiency of isopropyl alcohol was as high as 97.2%. The analyte and gliclazide (internal standard) were extracted from plasma samples with isopropyl alcohol and were separated on UPLC BEH C 18 with a mobile phase consisting of methanol and water (containing 0.1% formic acid). The method demonstrated good linearity at the concentrations ranging from 5 to 5,000 ng/mL. The intra-and interday relative standard deviations were >10%. Finally, the method was successfully applied to a pharmacokinetic study of homemade stealth HA-based NPs in rats following intravenous administration.
Introduction
Doxorubicin (Dox) is one of the most important anticancer agents and has been used extensively in the treatment of various cancers including bladder, breast, liver, bile duct and liver cancers (1) . However, the clinical use of Dox is hampered by the cardiotoxicity and nephrotoxicity (2) . To improve the anticancer activity and reduce the side effects of Dox, various drug delivery systems have been developed, such as micelle (3) (4) (5) , drug-conjugate (6) (7) (8) and liposome (9) . Recently, much attention has been paid to active targeting nanoassemblies, which enhance tumor cell-specific delivery and reduce off-target adverse effects to normal cells (10, 11) . Among various targeting moieties, hyaluronic acid (HA) is widely applied as a "magic targeting ligand" for nanoparticulate drug delivery systems, because of its biocompatible, biodegradable and CD44-targeting properties (12) (13) (14) (15) . However, the main drawback of HA-based nanoparticles (NPs) for cancer treatment is that most of them are captured by liver and spleen after systemic administration (16, 17) . In our previous study, a novel stealth hyaluronic acid-cyclodextrin NPs for Dox loading has been developed for improving the long blood circulation of NPs, enhancing antitumor effect and reducing toxicity of Dox (18) .
To study the pharmacokinetic and biodistribution profile of the Dox-loaded NPs, various quantification methods of Dox have been reported, such as high performance liquid chromatography (HPLC) (19) (20) (21) and liquid chromatography-tandem mass spectrometry (LC-MS-MS) methods (22) (23) (24) (25) (26) (27) . However, these methods had some drawbacks, for example, a long single run time, large volumes of blood sample and low sensitivity. Thus, the aim of the study is to develop and validate a rapid, effective NPs-breaking and sensitive, selective UPLC-MS-MS method for evaluating the pharmacokinetic profiles of the homemade stealth HA NPs in rats. In our study, isopropyl alcohol was used as NPs-breaking solvent for extracting Dox from homemade NPs in rat plasma, which also acts as protein-precipitating solvents, and the NPs-breaking extraction efficiency was as high as 97.2%. Compared with the previous reported methods, the validated method used a shorter analytical time (3.0 min per sample) and a lower plasma volume (50 µL). Finally, the established method was successfully employed to a pharmacokinetic study after an intravenous administration of homemade stealth HA NPs. 
Experimental

Preparation of the Dox-loaded NPs
We first synthesize a new double-hydrophilic copolymer by conjugating HP-β-cyclodextrin with HA, and it was further pegylated with adamantyl-peg (ADA-PEG) to form inclusion complex HA-HPCD/ ADA-PEG, termed as HCPs. The supramolecular nanoassemblies were fabricated by host-guest and polar interactions between HCPs and Dox, with vitamin E succinate (VES) being a nanobridge. Then, the Dox-loaded NPs were prepared using the emulsion solvent evaporation method. In general, a mixture of VES (1 mg/mL) and Dox (0.5 mg/mL) was dissolved in 2 mL dichloromethane (DCM). The organic solution was poured into 4 mL water phase, consisting of 10 mg HCPs under a probe sonication at 100 W for 180 s. The emulsion was allowed to stir magnetically at room temperature for 24 h to evaporate organic solvent. The final nanosuspensions were filtered through 0.45 µm syringe filter, centrifuged at 13,000 rpm for 10 min to remove the unencapsulated DOX, and then the Dox-loaded NPs were obtained (28) .
UPLC-MS-MS conditions
Analyses were performed by the ACQUITY UPLC system (Waters Corp., Milford, MA, USA) with a cooling autosampler and a column oven. An ACQUITY UPLC BEH C 18 column (50 mm × 2.1 mm, 1.7 µm; Waters Corp.) was used. The chromatographic separations were obtained by gradient elution with a mobile phase consisting of Solvent A (methanol) and Solvent B (water containing 0.1% formic acid). The gradient conditions of the mobile phase were followed: 0 min 55% B, 0.4 min 40% B, 0.8 min 5% B and 2.2 min 55% B. The flow rate set 0.2 mL/min and the column temperature were conditioned at 40°C, the autosampler temperature was maintained at 7°C, the sample volume injected was 5 µL with the partial loop mode for sample injection. The chromatographic run time of each sample was 3.0 min. From 1.1 to 2.4 min, the eluent was injected into detector, and the remainder was diverted to waste.
A Water Tandem Quadrupole (TQ) Detector (Waters) was used to detect the separated compounds. The mass spectrometer was operated with an ESI interface in positive ionization mode for Dox and IS. The ionization source conditions were followed: capillary voltage 3.0 kV, cone voltage 25 V, source temperature 120°C and desolvation temperature 350°C. The cone and desolvation gas flow rates were 50 and 400 L/ h, respectively. Argon was used as collision gas at a pressure of about 0.0033 mbar. Under these UPLC-MS/MS conditions, the compounds were analyzed by multiple monitoring (MRM) of the transitions of m/ z 544 → 397 for Dox and m/z 324 → 127 for IS, respectively.
Preparation of standards and quality control samples
Standard stock solutions of Dox and IS were both prepared in methanol. The Dox solution was diluted with the mobile phase consisting of 45% A and 55% B to provide working standard solution of desired concentrations. Calibration standards were prepared by appropriate dilution of stock solutions with blank rat plasma. The effective concentrations in plasma samples ranged from 5 ng to 5,000 ng/mL (5, 50, 100, 500, 1,000, 2,000 and 5,000 ng/mL). The quality control (QC) samples were prepared at concentrations of 50, 500 and 4,000 ng/mL in the same way to the calibration standards. These calibration standard samples and QC samples were stored at −20°C.
Extraction method
The extraction method was optimized by studying the NPs-breaking efficiency of Dox-loaded (non) pegylated hyalurionic acid (HA)-based NPs with the protein precipitation (PPT) and liquid-liquid extraction (LLE) method. Blank rat blood plasma spiking with Dox-loaded NPs (1,000 ng/mL) was processed with PPT with methanol (containing 20% w/w zinc sulfate), methanol and acetonitrile, respectively. Also, isopropyl alcohol, DCM, methyl tert-butyl ether and diethyl ether were used as extraction solvents in the process of LLE. Micelle breaking efficiency was determined by the ratio between the peak areas of Dox-loaded NPs after breaking to the peak area of Dox solution with the same Dox concentration.
Sample preparation
After spiking 50 µL the mobile phase consisting of 45% A and 55% B, 50 µL of IS solution (in methanol 200 ng/mL) and 50 µL of 0.05 M borax sodium carbonate buffer ( pH 10.8) into 50 µL of the plasma sample, the mixed samples were extracted with 2 mL isopropyl alcohol. The mixture was vortexed for about 3 min and then centrifuged at 13,000 × g for 10 min. The organic layer was evaporated to dryness at 35°C under a gentle stream of nitrogen. The residue was redissolved in 100 µL mobile phase and vortexed for 2 min. A 5 µL aliquot of the sample was then injected into the UPLC-MS-MS system for assay.
Method validation
The method used for quantitative determination of Dox in the rat blood sample was validated for selectivity, linearity, LLQQ, accuracy, precision, extraction recovery, matrix effect and stability. The different validation parameters and the values for accepting the range of validation parameters were in terms of international guidelines.
To study possible interferences with the analytes, selectivity was studied by comparing chromatograms of six different batches of blank plasma from six rats with those of corresponding standard blood plasma sample spiked with Dox (50 ng/mL) and IS (200 ng /mL) and a plasma sample obtained after intravenous administration.
Calibration curves were prepared with seven standard plasma samples over the range 5-5,000 ng/mL. The lower limit of quantification (LLOQ) was defined as a signal/noise ratio of ≥10. The precision and accuracy were evaluated by analyzing six samples that were prepared in six replicates, and the results should be <20%.
The precision and accuracy of the method were determined by measuring QC samples at three concentration levels (50, 500 and 4,000 ng/mL) on three separate days. The accuracy was expressed by the relative error (RE), and the precision was assessed by the relative standard deviation (RSD). The matrix effect was investigated by comparing the ratio between the peak area of Dox at three QC concentration levels (50, 500 and 4,000 ng/mL, n = 6) spiked in postextracted blank blood sample (A) and that of Dox spiked in the mobile phase at the corresponding standard solutions (B).
The extraction recovery of Dox was measured by comparing the mean peak area of the regularly prepared samples at three concentrations (50, 500 and 4,000 ng/mL) with the mean peak area of spike-after-extraction plasma samples. The extraction recovery of IS was assessed by the same way at the concentration of 200 ng/mL. The stability of processing (three freeze-thaw cycles), sample storage (at room temperature for 4 h, at −80°C for 1 month), post-treatment (the extracted samples at 7°C for 24 h) of low, medium and high QC samples and the percentage of concentration deviation were calculated.
Pharmacokinetic study
The developed method was used to determine the plasma concentrations of Dox in the NPs after intravenous administration in rats. Healthy male Sprague-Dawley rats (220-250 g) fasted, but free access to water for 12 h before the administration was used in the study. The animal studies were approved by the Shenyang Pharmaceutical University Animal Care and Use Committee. The rats were divided into two groups and were injected via lateral saphenous vein with the formulation of pegylated and non-pegylated NPs with equivalent Dox dose ( 
Results
Method development
In this work, LC-MS-MS operation parameters were carefully optimized for the determination of Dox and GLZ (IS). The standard solution of Dox and GLZ was directly infused into the mass spectrometer with the mobile phase. It was found that the ESI source produced a better response than the APCI source for Dox and GLZ, and both analytes showed good mass spectrometric responses in the positive ESI mode. In the precursor ion full-scan spectra, predominantly protonated ions were 544.58 for Dox and 324.39 for IS, respectively. In addition, the MS-MS parameters, including cone voltage, capillary voltage, desolvation temperature and collision energy, were carefully optimized to get the highest intensity of protonated molecules. The mass transitions m/z 544 → 397 for Dox and m/z 324 → 127 for IS were selected for the MRM analysis, respectively. The production mass spectra of these compounds are shown in Figure 1 .
Methanol showed higher mass spectrometric response and lower background noise than acetonitrile and then was chosen as the organic phase. Moreover, adding a small amount of formic acid in the mobile phase resulted in improved peak shape of Dox and IS. To avoid the matrix effect and obtain a high sensitivity and throughput, a gradient dilution program was finally adopted in this work. The retention time of Dox and IS was as short as 1.17 and 1.59 min, respectively.
The PPT using methanol with or without ZnSO 4 , LLE and solidphase extraction (SPE) were commonly used to extract Dox from the biological samples in the previous studies (19, 23, 25, (29) (30) (31) (32) . Compared with PPT and LLE methods, SPE suffered from low efficiency and high cost. Thus, in this study, we focused on PPT and LLE. NPs-breaking extraction efficiency was one of the most important parameters to assay the total Dox concentrations in plasma. NPs-breaking efficiency of Dox-loaded NPs with PPT and LLE methods are shown in Table I . In general, the NPs-breaking efficiency using the LLE method was higher than that of PPT. Although Liu and Zhang reported that the micelles-breaking efficiency of PTX-loaded HA-C18 and Dox-loaded pegylated polymer micelles by PPT was as high as 97.7 and 99.2%, respectively (25, 33) , in this study, the NPs-breaking efficiency was lower than 50% with PPT, even the volume ratio of methanol and NP was 10:1 and the ultrasonic emulsion time was 1 h at 40 kHz. These findings suggested that PPT could not destroy the HA-based NPs completely and the Dox concentration could not be determined precisely for reflecting the total Dox concentration in plasma. However, the NPs-breaking efficiency of pegylated and nonpegylated NPs using LLE with isopropyl alcohol were over 97%, and these results indicated that Dox was almost completely extracted from the HA-based NPs using isopropyl alcohol as NPs-breaking solvent, which also acting as protein-precipitation agent. In addition, during the optimization course of the method development, we found that the amount of extraction solvents affected the extraction recovery of Dox, and when the volume of extraction solvent was more than 2 mL, the extraction recovery was over 90% for Dox.
Method validation
Selectivity
The typical chromatograms of blank plasma, blank plasma spiked with Dox (50 ng/mL) and IS (200 ng/mL) and plasma sample after i.v. administration of Dox solution after 2 h are shown in Figure 2 . It showed that there was no interference from endogenous substances in plasma.
Linearity and LLOQ
The liner regression of the peak area ratios versus concentration was fitted over the concentration range of 5-5,000 ng/mL for Dox. Linear regressions were performed with 1/x 2 as the weighting factor. Typical equations for the calibration curves were as follows: y = 0.0120x + 0.0046, where y is the peak area ratio of Dox to IS and x (ng/mL) is the plasma concentration of Dox. The present UPLC-MS-MS method showed an LLQQ of 5 ng/mL with an accuracy of 4.12% in terms of RE and a precision of 1.21% in terms of RSD (n = 6).
Precision and accuracy
The intraday and interday precision and accuracy for Dox from QC samples are shown in Table II . The intra and interday precisions were all below 10%, and the maximum deviation of accuracy was 4.51%, indicating that the present method had good precision and accuracy.
Extraction recovery and matrix effect
The extraction recoveries of Dox at the concentrations of 50, 500 and 4,000 ng/mL (n = 6) were more than 100%. The extraction recovery of IS was 99.87%. The matrix effect of Dox and IS ranged from 90 to 100%, suggesting that there was no significant matrix effect. 
Stability
The stability of Dox in the rat plasma under different storage conditions is shown in Table III . The REs of all the samples were within 10%, indicating that Dox showed no significant degradation under the previously described conditions.
Pharmacokinetic study
The method was successfully applied to the pharmacokinetic study of Dox-loaded pegylated and non-pegylated HA-based NPs in rats following a single intravenous administration of Dox at a single dose of 5 mg/kg. The profile of the mean plasma concentration of Dox versus time is shown in Figure 3 . The pharmacokinetics parameters (mean ± SD, n = 5) were calculated by DAS 2.0 software (Shanghai, China) and were summarized in 
Conclusion
We have developed and validated a NPs-breaking and LC-MS-MS method for quantitation of Dox in rat plasma. The pretreatment method of blood samples used the LLE breaking process with isopropyl alcohol as NPs-breaking and protein-precipitant solvents, and the NPs-breaking extraction efficiency of isopropyl alcohol was as high as 97.2%. Compared with the previous reported methods, the validation results showed a shorter analytical time (3.0 min per sample) and used a lower plasma volume (50 µL). The validated method was successfully applied to a preclinical pharmacokinetic study of the homemade stealth HA-based NPs in rats following intravenous administration. The results indicated that pegylation could significantly prolong the circulation time of HA-based NPs. 
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